Firazyr icatibant: Phase III started

Shire disclosed that in June it began the double-blind, placebo-controlled, U.S. Phase III FAST-3 trial to evaluate subcutaneous Firazyr in patients with acute attacks of HAE. Earlier this year, Shire...